×
About 314 results
Endometriosis: Diagnostic and Treatment Challenges
https://www.medscape.com/viewarticle/923259

Dec 30th, 2019 - Endometriosis is a chronic, benign gynecologic disease that is diagnosed when endometrial glands and stroma are found in extrauterine locations. Affecting as many as 1 in 7 women, endometriosis is associated with pelvic symptoms, dysmenorrhea, chronic pelvic pain, dyspareunia, intestinal or urinary tract problems, and infertility. Despite a host of well-described symptoms, the diagnosis is typi...

Fractional CO2 Laser Treatment Appears to Relieve Genitourinary Syndrome in Postmenopausal Women
https://www.medscape.com/viewarticle/923194

Dec 30th, 2019 - NEW YORK (Reuters Health) - Fractional CO2 laser treatment appears to relieve symptoms of genitourinary syndrome of menopause in postmenopausal women, according to new findings. An estimated 50% of women experience genitourinary syndrome of menopause (GSM), which manifests as vaginal laxity, dryness, dyspareunia, itching, burning, urinary incontinence and other symptoms. Local therapies, includ...

Vulvovaginal Atrophy in Menopause Linked to Depression, Anxiety
https://www.medscape.com/viewarticle/921560

Nov 20th, 2019 - NEW YORK (Reuters Health) - Women with vulvovaginal atrophy (VVA) have a greater risk of depression, major depressive disorder (MDD) and anxiety than those without the condition, according to new findings. Women aged 45-54 with VVA were at particularly increased risk, Erick Moyneur of StatLog Econometrics, Inc., in Montreal and colleagues report in Menopause, online November 4. "While this stud...

Ask About Sexual Function in Breast Cancer Patients on Endocrine Tx
https://www.medscape.com/viewarticle/920631

Oct 30th, 2019 - SAN FRANCISCO — Breast cancer patients taking endocrine therapy to prevent a relapse have long reported adverse effects on sexual function, but a new study suggests that this issue affects nearly all of these women. Just about all (99%) of the postmenopausal women who took part in the study scored low on the Female Sexual Function Index (FSFI), indicating a high degree of sexual dysfunction, in...

Fast Five Quiz: Sexual Dysfunction
https://www.medscape.com/viewarticle/916566

Aug 11th, 2019 - An estimated 43% of women and 31% of men in the United States alone report some degree of sexual dysfunction. Although sexual dysfunction is common worldwide, many affected individuals are resistant to discussing such issues with their healthcare providers. The term "sexual dysfunction" refers to problems or conditions that prevent or inhibit pursuit or enjoyment of sexual activity. Such issues...

Product Update: Osphena’s NDA, new hysteroscope, TempSure RF technology, Resilient stirrup covers
https://www.mdedge.com/obgyn/article/206099/gynecology?channel=247

Aug 8th, 2019 - OSPHENA HAS NEW INDICATION Duchesnay Inc. has added moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause, to the indication of Osphena TM (ospemifene).

Survey: Patient-provider communication regarding dyspareunia disappoints
https://www.mdedge.com/familymedicine/article/203721/female-sexual-dysfunction/survey-patient-provider-communication?channel=268
MDedge ObGyn; Sharon Worcester

Jun 27th, 2019 - NASHVILLE, TENN. – Many women with endometriosis experience dyspareunia, but they are largely unsatisfied when it comes to discussions with health care providers about their symptoms, the results of an online survey suggest.

Managing Endometriosis Pain with Non-Invasive Treatment Options
https://www.mdedge.com/obgyn/article/201709/endometriosis/managing-endometriosis-pain-non-invasive-treatment-options?channel=266

Jun 17th, 2019 - Endometriosis is an estrogen-dependent disease1 that affects an estimated one in 10 women of reproductive age. 2 In an international multicenter survey of 931 patients treated at 12 tertiary care centers in 10 countries, it was reported that 7 out of 10 endometriosis patients experience unresolved pain despite management.

Modern surgical techniques for gastrointestinal endometriosis
https://www.mdedge.com/obgyn/article/202298/endometriosis/modern-surgical-techniques-gastrointestinal-endometriosis/page/0/2?channel=218

Jun 4th, 2019 - To date, no optimal hormonal regimen has been established for the treatment of bowel endometriosis. Vercellini and colleagues demonstrated that progestins with and without low-dose estrogen improved symptoms of dysmenorrhea and dyspareunia.

Ospemifene, an oral SERM for dyspareunia of menopause: Is it being underutilized?
https://www.mdedge.com/obgyn/article/193519/dyspareunia/ospemifene-oral-serm-dyspareunia-menopause-it-being-underutilized?channel=247
Simon, James A.

Jan 30th, 2019 - Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia. Read the supplement and earn CME credit for your knowledge of the following: The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.

Gabapentin Improves Sexual Function in Some With Vulvodynia
https://www.medscape.com/viewarticle/908087

Jan 21st, 2019 - Treatment with gabapentin improves sexual function in women with persistent, unexplained pain in the vulva (vulvodynia) who have increased pelvic muscle pain on examination.   "Previous studies have suggested gabapentin reduces the pain of fibromyalgia...[and] our theory was that reducing pelvic floor muscle pain might reduce vulvodynia pain overall and thus improve sexual function," lead autho...

Managing menopausal vasomotor and genitourinary symptoms after breast cancer
https://www.mdedge.com/fedprac/article/196511/preventive-care/acc-aha-release-first-cardiovascular-disease-primary/page/0/2?channel=194

Jan 8th, 2019 - Nonhormone therapies Topical lidocaine for insertional dyspareunia has been studied in postmenopausal women with breast cancer with severe GSM, dyspareunia, increased sexual distress scores, or abnormal sexual function with improvement seen using 4% aqueous lidocaine versus saline applied with a cotton ball to the vestibule for 3 minutes before vaginal penetration. 9 Vaginal laser therapy has th.

Rate of sling removal 9 years after MUS for SUI over 3%
https://www.mdedge.com/surgery/article/178761/gynecology/rate-sling-removal-9-years-after-mus-sui-over-3?channel=39313
Nicola Garrett

Nov 2nd, 2018 - The long-term mesh removal rate in women with a midurethral mesh sling (MUS) insertion for treating stress urinary incontinence (SUI) was 3. 3%, a British study found.

No signal for CV, breast effects with bioidentical vaginal estrogen for dyspareunia
https://www.mdedge.com/familymedicine/article/176883/menopause/no-signal-cv-breast-effects-bioidentical-vaginal-estrogen?channel=39313
Clinical Endocrinology News; Kari Oakes

Oct 10th, 2018 - Menopausal women with dyspareunia who received a bioidentical estradiol vaginal insert experienced no cardiovascular or breast effects that would suggest significant systemic absorption. Dr.

Lasers Promising for Genitourinary Syndrome of Menopause
https://www.medscape.com/viewarticle/903074

Oct 5th, 2018 - SAN DIEGO — Vaginal dryness and dyspareunia, along with other symptoms of genitourinary syndrome of menopause, can be safely and effectively treated with laser therapy, preliminary results from a small study show. Solid evidence for the laser treatment of genitourinary syndrome of menopause has been sparse, but it is increasing, said investigator Eric Sokol, MD, from the Stanford University Sch...

For dyspareunia, intravaginal prasterone may work best soon after menopause
https://www.mdedge.com/internalmedicine/article/176536/menopause/dyspareunia-intravaginal-prasterone-may-work-best-soon?channel=39313
Kari Oakes

Oct 5th, 2018 - Neither age nor previous hormone therapy had statistically significant associations with the effect of intravaginal prasterone on dyspareunia severity, according to a new subgroup analysis of clinical trial data. In a trend that did not reach statistical significance, though, women who were further away from menopause reported numerically smaller improvements in dyspareunia, compared with basel.

What works best for genitourinary syndrome of menopause: vaginal estrogen, vaginal laser, or combined laser and estrogen therapy?
https://www.mdedge.com/obgyn/article/171599/menopause/what-works-best-genitourinary-syndrome-menopause-vaginal-estrogen/page/0/1?channel=218

Aug 1st, 2018 - Laser treatment improved dryness, burning, and dyspareunia but caused more pain All 3 treatment groups showed statistically significant improvement in vaginal dryness at 20 weeks, but only the laser-alone arm and the laser plus estriol arms showed improvement in dyspareunia and burning. The total FSFI scores improved significantly only in the laser plus estriol arm (TABLE).

A multimodal treatment for vestibulodynia: TENS plus diazepam
https://www.mdedge.com/obgyn/article/169895/gynecology/multimodal-treatment-vestibulodynia-tens-plus-diazepam?channel=27970
Dan Watson

Jul 10th, 2018 - Transcutaneous electrical nerve stimulation (TENS) was effective at treating chronic vulvar pain at the vestibule in combination with vaginal diazepam and with placebo in a randomized, double-blind, placebo-controlled trial. In the TENS/diazepam and TENS/placebo groups, participants reported significant improvements from baseline in pain and sexual functioning by questionnaire and visual analog.

Your age-based guide to comprehensive well-woman care
https://www.mdedge.com/obgyn/article/64891/practice-management/your-age-based-guide-comprehensive-well-woman-care/page/0/4?channel=262
Clinical Neurology News;

Jun 11th, 2018 - The common sexual disorders in women are categorized as desire, arousal, orgasm, and pain disorders. There are two desire disorders: hypoactive sexual desire disorder and sexual aversion disorder.

Morning Break: Nipah 'Not Alarming'; DEA's Opioid Perspective; Blind Car Racing
https://www.medpagetoday.com/infectiousdisease/publichealth/73249

Jun 4th, 2018 - Note that some links may require subscriptions. Eighteen cases of Nipah virus infection in southern India, 16 fatal, but the local government says the situation is "not alarming" anymore. (NDTV) Faster me-toos? As part of the government's efforts to slow soaring drug prices, FDA Commissioner Scott Gottlieb says he wants to shorten the time that first-in-class drugs have the market to themselves...